Vera Therapeutics (VERA) Expected to Post Quarterly Earnings on Tuesday

Vera Therapeutics (NASDAQ:VERA) is expected to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Vera Therapeutics to announce earnings of ($1.58) per share and revenue of $1.2810 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 12:30 PM ET.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the previous year, the business posted ($0.81) EPS. On average, analysts expect Vera Therapeutics to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA opened at $32.10 on Monday. Vera Therapeutics has a 12-month low of $19.07 and a 12-month high of $56.05. The stock has a market cap of $2.30 billion, a PE ratio of -5.79 and a beta of 0.92. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average of $36.91 and a 200 day moving average of $39.58.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 46,250 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the transaction, the chief executive officer owned 151,994 shares of the company’s stock, valued at $6,429,346.20. This represents a 23.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 83,250 shares of company stock valued at $3,337,770. Corporate insiders own 15.90% of the company’s stock.

Institutional Trading of Vera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of VERA. Massar Capital Management LP purchased a new position in shares of Vera Therapeutics during the 2nd quarter worth approximately $377,000. Jain Global LLC purchased a new stake in Vera Therapeutics in the fourth quarter valued at approximately $361,000. Commonwealth Equity Services LLC purchased a new stake in Vera Therapeutics in the fourth quarter valued at approximately $311,000. Virtu Financial LLC acquired a new position in Vera Therapeutics during the fourth quarter worth $297,000. Finally, Virtus Investment Advisers LLC lifted its stake in Vera Therapeutics by 5.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after purchasing an additional 290 shares in the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on VERA shares. TD Cowen boosted their target price on Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. HC Wainwright upped their price target on Vera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Friday, July 17th. Finally, Guggenheim boosted their price objective on Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $84.58.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.